Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

Neurology ◽

10.1212/wnl.43.4.662 ◽

1993 ◽

Vol 43 (4) ◽

pp. 662-662 ◽

Cited By ~ 830

Author(s):

D. W. Paty ◽

D.K.B. Li ◽

◽

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

Neurology ◽

10.1212/01.wnl.0000407006.93844.fb ◽

2011 ◽

Vol 77 (15) ◽

pp. 1431-1431

Author(s):

D. W. Paty ◽

D. K. B. Li ◽

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial

Neurology ◽

10.1212/wnl.43.4.655 ◽

1993 ◽

Vol 43 (4) ◽

pp. 655-655 ◽

Cited By ~ 1711

Author(s):

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Trial ◽

Clinical Results ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial

Clinical Therapeutics ◽

10.1016/j.clinthera.2015.10.014 ◽

2015 ◽

Vol 37 (12) ◽

pp. 2780-2787 ◽

Cited By ~ 16

Author(s):

Angela Applebee ◽

Andrew D. Goodman ◽

Angeli S. Mayadev ◽

Francois Bethoux ◽

Myla D. Goldman ◽

...

Keyword(s):

Multiple Sclerosis ◽

Extended Release ◽

Controlled Trial ◽

Walk Distance ◽

Double Blind ◽

Double Blind Placebo ◽

Post Hoc Analysis ◽

Post Hoc ◽

Minute Walk Distance ◽

Minute Walk

Randomised, double blind, placebo controlled study of interferon beta -1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp.67.4.451 ◽

1999 ◽

Vol 67 (4) ◽

pp. 451-456 ◽

Cited By ~ 18

Author(s):

C. Liu ◽

L. D Blumhardt

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet Neurology ◽

10.1016/s1474-4422(11)70299-x ◽

2012 ◽

Vol 11 (2) ◽

pp. 131-139 ◽

Cited By ~ 54

Author(s):

David H Miller ◽

Thomas Weber ◽

Richard Grove ◽

Claire Wardell ◽

Joseph Horrigan ◽

...

Keyword(s):

Multiple Sclerosis ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: A randomized, double-blind, placebo-controlled trial

American Journal of Ophthalmology ◽

10.1016/j.ajo.2004.12.093 ◽

2005 ◽

Vol 139 (3) ◽

pp. 582

Author(s):

A. Achiron ◽

I. Kishner ◽

I. Sarova-Pinhas ◽

H. Raz ◽

M. Faibel ◽

...

Keyword(s):

Multiple Sclerosis ◽

Intravenous Immunoglobulin ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Immunoglobulin Treatment

Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double-blind, placebo-controlled trial

Journal of Cellular Physiology ◽

10.1002/jcp.26301 ◽

2018 ◽

Vol 233 (7) ◽

pp. 5222-5230 ◽

Cited By ~ 16

Author(s):

Sanam Dolati ◽

Leili Aghebati-Maleki ◽

Majid Ahmadi ◽

Faroogh Marofi ◽

Zohreh Babaloo ◽

...

Keyword(s):

Multiple Sclerosis ◽

Expression Profile ◽

Mirna Expression ◽

Controlled Trial ◽

Mirna Expression Profile ◽

Double Blind ◽

Double Blind Placebo

Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial

Clinical Nutrition ◽

10.1016/j.clnu.2016.08.015 ◽

2017 ◽

Vol 36 (5) ◽

pp. 1245-1249 ◽

Cited By ~ 85

Author(s):

Ebrahim Kouchaki ◽

Omid Reza Tamtaji ◽

Mahmoud Salami ◽

Fereshteh Bahmani ◽

Reza Daneshvar Kakhaki ◽

...

Keyword(s):

Multiple Sclerosis ◽

Metabolic Response ◽

Controlled Trial ◽

Probiotic Supplementation ◽

Double Blind ◽

Double Blind Placebo

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp.2003.010090 ◽

2004 ◽

Vol 75 (5) ◽

pp. 706-710 ◽

Cited By ~ 80

Author(s):

O Andersen

Keyword(s):

Multiple Sclerosis ◽

Low Dose ◽

Interferon Beta ◽

Progressive Multiple Sclerosis ◽

Secondary Progressive Multiple Sclerosis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Secondary Progressive ◽

Phase Iii Study